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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the
world in developed countries. Despite the intense research in the area of squamous cell carcinomas of head and
neck (HNSCC), long-term survival rate has not changed significantly in this malignancy during recent decades.
Methods: In this study, we focused on TP53 mutations in specific regions, including DNA-binding surface, to
determine whether mutations at specific locations of TP53 could be used to help in setting up prognosis and
response to therapy of head and neck squamous cell carcinoma patients. We analysed TP53 mutations in 46
HNSCC by PCR-SSCP and sequencing and characterized how different TP53 mutations affect the patient outcome.
Results: Tumours containing TP53 mutations in DNA-binding regions (L2, L3 and LSH motif) had a significantly
poorer prognosis and response to radiotherapy than tumours outside those regions. Disease-specific 5-year
survival of patients with TP53 mutations affecting DNA contacts was 43.5% while it was 77.8% (p < 0.05) in
patients with TP53 mutations in other residues not involved in DNA contact. Moreover, nodal metastasis were
more prevalent (although not statistically significantly) with TP53 mutations in DNA-binding surface regions. We
noticed that the patients with TP53 mutations in L3/LSH motifs had a significantly poorer response (11.4%
responding) to radiation than the patients with a wild type p53 (48.6%) or TP53 mutations outside the DNA-
binding regions (40%) (p < 0.05).
Conclusions: These data indicate that a TP53 mutation in L2, L3 or LSH is worth pursuing as a marker for
predicting prognosis and response to radiation among HNSCC patients.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is
one of the 10 most frequent malignancy in the world
and more than 500 000 new cases are reported annually
[1]. Despite the intense research in the area of squa-
mous cell carcinomas of head and neck (HNSCC), the
long-term survival rate has not changed significantly in
this malignancy during recent decades [2]. The initial
treatment approaches for a patient with HNSCC include
most often radiotherapy added to primary surgery one
way or another or as a definitive treatment of inoperable
disease [3]. In the past decade, the role of organ-preser-
vation protocols, with combined chemoradiation and
surgery for salvage, has increased. These protocols are
particularly effective for patients with moderately
advanced cancers of the larynx and pharynx who are
less than 70 years old and have a good performance sta-
tus [2]. Also technical improvements have decreased
late radiotherapy side-effects. Recently Nutting and co-
workers (2011) compared conventional radiotherapy to
parotid-sparing intensity-modulated radiotherapy
(IMRT) in patients with pharyngeal squamous cell carci-
noma and noticed significantly lower late side-effect rate
but did not report any survival advantage [4]. Anti-
EGFR mAb cetuximab has shown promising antitumour * Correspondence: jenni.peltonen@oulu.fi
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combinations and schedule is still to be found [5].
The abrogation of p53 function through the mutation
of its gene, TP53 [6], the loss of heterozygosity of TP53
[7] or interaction with viral proteins [8], is one of the
most common molecular alterations in squamous-cell
carcinoma of the head and neck [9]. The TP53 tumour
suppressor gene in chromosome 17p13.1 encodes the
p53 protein, which functions primarily as a multi-target
transcription factor. The p53 protein is known to be
involved in various cellular functions including cell-cycle
regulation, senescence, apoptosis, repair of DNA damage
caused by genotoxic agents, angiogenesis, and regulation
of oxidative stress and glucose metabolism [10-13]. Loss
of the p53 function allows proliferation of the cells with
a DNA-damage and promotes neoplasia in transgenic
p53 null mice [14]. TP53 gene alterations are commonly
found in head and neck cancers, and most of the pub-
lished mutations affect the p53-DNA interactions,
resulting in a partial or complete loss of transactivation
functions [15]. TP53 differs from other tumour suppres-
sor genes in its mode of inactivation. While most
tumour suppressor genes are inactivated by mutations
leading to absence of protein synthesis or production of
a truncated protein, more than 80% of TP53 alterations
are missense mutations that lead to the synthesis of a
stable full-length protein [15]. The location of the
resulting amino-acid substitution is usually within the
central DNA-binding domain of the p53, resulting in a
loss of DNA-binding activity with consequent failure to
transcriptionally activate target genes [16].
In the past 10 years, systematic data from the func-
tional assays have been generated and integrated in the
TP53 database managed by the International Agency for
Research on Cancer (IARC) (http://www-p53.iarc.fr/)
[17]. Most mutant p53 proteins have lost their DNA-
binding activity, leading to a loss of their growth inhibit-
ing and apoptotic properties. The role of p53 as a prog-
nostic marker of squamous cell carcinoma of the head
and neck is controversial. The possible reasons for this
include small numbers of patients studied, insufficient
clinical follow-up, variable laboratory techniques used,
or analysis of TP53 data based on insufficient mutation
characterization [15,18].
In the present study, we pursue the clinical importance
of TP53 mutation types in head and neck cancer. We
analyzed TP53 mutations in 46 patients with head and
neck squamous cell carcinomas (HNSCC) by polymerase
chain reaction-single-strand conformation polymorphism
(PCR-SSCP) and sequencing as earlier described [19].
The aim of this study was to examine whether specific
TP53 mutation types were associated with the clinical
outcome of head and neck cancer, such as lymph node
metastasis, prognosis and therapy of the patients.
Materials and methods
Patients and tumours
In this same population, we have investigated earlier p53
aberrations in association with environmental exposures
[19]. This study population consists of 46 patients trea-
ted for primary head and neck squamous cell carcinoma
enrolled as patients in the University Hospital of Oulu,
Finland between the years 1994 and 1996. The patients
were recruited to the study before any treatment was
started. We wanted a long follow-up time to clarify
long-time survival differences between specific TP53
mutations. Clinico-pathological variables are given in
Table 1. The age of the patients varied greatly (28-85
years). The stage of the disease, tumour size and lymph
node involvement were determined according to the
International Union Against Cancer TNM classification
(1997) [20]. The histological grade of the tumours were
reviewed and classified according to the World Health
Organization classification of head and neck tumours
[21]. The treatment was carried out according to the
stage of the disease and the routine clinical treatment
protocol (Table 2). 33 patients received 50 Gy or more
Table 1 Clinicopathological variables
Patient characteristics n
All patients 46
Sex
Male 31
Female 15
Age, years
≤39 3
40-65 23
≥66 20
Anatomical location
Oral cavity 14
Larynx 24
Pharynx 6
Others 2
Grade
Grade 1 10
Grade 2 29
Grade 3 7
TNM classification
T1-2 29
T3-4 17
N0 23
N+ 23
Stage
I6
II 9
III 20
IV 11
Earlier published in Peltonen et al. Head & Neck Oncology 2010 2:36 [19].
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Page 2 of 10Table 2 Features of the primary tumours regarding primary treatment regimen, follow up time and cause of death
Tumour Age Disease
site
Stage TP53 gene status Surgery Radiation-
therapy (radical)
Disease free in
months
Overall survival
in months
Death related
to HNSCC
1 65 larynx 2 wild type Yes Yes 166 166 No
2 61 larynx 3 wild type Yes Yes 145 145 No
3 56 pharynx 3 mutation outside L2/
L3/LSH motif
Yes Yes 156 156 No
4 65 larynx 3 mutation outside L2/
L3/LSH motif
Yes Yes 121 121 No
5 48 pharynx 3 wild type Yes Yes 74 Yes
7 48 oral
cavity
3 wild type Yes Yes 158 158 No
8 75 oral
cavity
2 wild type Yes Yes 6 15 Yes
9 28 oral
cavity
3 mutation outside L2/
L3/LSH motif
Yes Yes 155 155 No
10 58 oral
cavity
3 wild type Yes Yes 11 8 Yes
12 78 oral
cavity
2 mutation in L2/L3/LSH
motif
Yes No 7 40 Yes
13 83 larynx 2 wild-type Yes Yes 51 51 No
14 45 larynx 1 wild type Yes Yes 122 122 No
16 85 pharynx 3 mutation in L2/L3/LSH
motif
Yes Yes 32 32 No
17 74 oral
cavity
3 wild type Yes No 3 12 Yes
18 72 larynx 1 mutation outside L2/
L3/LSH motif
Yes Yes 164 164 No
19 57 larynx 4 mutation outside L2/
L3/LSH motif
Yes Yes 24 24 No
20 62 oral
cavity
3 mutation in L2/L3/LSH
motif
No only palliative 0 1 Yes
26 68 larynx 4 wild type Yes Yes 9 18 Yes
28 65 oral
cavity
4 mutation in L2/L3/LSH
motif
No only palliative 6 22 Yes
29 33 oral
cavity
3 mutation outside L2/
L3/LSH motif
Yes Yes 157 157 No
31 71 oral
cavity
1 mutation in L2/L3/LSH
motif
Yes No 20 84 Yes
32 39 oral
cavity
3 mutation in L2/L3/LSH
motif
Yes Yes 37 40 Yes
39 68 larynx 4 wild type p53 Yes Yes 11 19 Yes
41 53 nose 2 wild type p53 Yes Yes 7 18 Yes
43 74 larynx 2 mutation in L2/L3/LSH
motif
No Yes 154 154 No
45 70 pharynx 3 wild type p53 Yes Yes 142 142 No
46 62 larynx 1 mutation outside L2/
L3/LSH motif
Yes Yes 135 135 No
49 62 oral
cavity
1 mutation in SSCP Yes No 60 67 Yes
50 49 larynx 3 wild type p53 Yes Yes 122 122 No
51 63 larynx 2 mutation outside L2/
L3/LSH motif
Yes Yes 109 109 No
52 63 larynx 4 wild type p53 Yes Yes 20 30 Yes
53 74 oral
cavity
4 mutation in L2/L3/LSH
motif
Yes No 35 37 Yes
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tional fractionation, five patients were treated with radi-
cal surgical operation without other treatments, and five
patients received only radiotherapy (50-64 Gy). No
patients were treated with adjuvant chemotherapy.
Three of the patients had an advanced carcinoma and
received only palliative treatment.
Ethical aspects
The study design was approved by the local Ethics
Committee of the Medical Faculty at the University of
Oulu, Finland and a written informed consent was
obtained from all patients entering the study.
p53 immunohistochemistry
Paraffin embedded sections (4 μm) from the primary
tumours of head and neck carcinomas were stained
using the avidin-biotin-immunoperoxidase technique.
Paraffin sections were incubated at 37°C for at least 4
hours, dewaxed (Histo- Clear
®, National Diagnostic,
Atlanta, GA, USA) and hydrated. Endogenous peroxi-
dase activity was blocked by incubating the slides in
0.1% hydrogen peroxidase/methanol for 20 min and
non-specific binding was blocked with 10% goat serum
for 15 min. A mouse monoclonal antibody (DO-7,
Novocastra Laboratories Ltd., Newcastle upon Tyne,
UK) for p53 was used as a primary antibody (1:300)
mixed with 1% bovine serum albumin. The antibody
recognizes both wild type and mutant forms of human
p53 and the epitope is located between amino acid resi-
dues 19 and 26. The specimens were incubated for 60
minutes at room temperature in a humidified chamber
after which the immunohistochemical staining was con-
tinued using Histostain-bulk kit
® (Zymed, San Fran-
cisco, CA, USA) according to the manufacturer’s
protocol. Biotinylated antimouse IgG was used as a sec-
ondary antibody and the peroxidase was introduced as a
streptavidin conjugate. The slides were washed thor-
oughly with phosphate-buffered saline between all stages
of the procedure. The antibody reaction was visualised
by using a fresh substrate solution containing ami-
noethyl carbazol substrate kit (AEC-kit
®,Z y m e d ,S a n
Francisco, CA, USA). The sections were counterstained
with hematoxylin, dehydrated and mounted in glycerol-
vinyl-alcohol (GVA mount
®; Zymed). For negative con-
trols the primary antibody for p53 was replaced with
mouse non-immuno IgG and each set of staining always
included a separate known positive control sample.
Evaluation of the p53 immunostaining
The slides were analysed separately by two independent
observers blinded from the clinical data. The immunor-
eactivity in the malignant cells in each section was
graded according to the extent and amount of the posi-
tive staining from 0 to ++++. The immunoreactivity in
the malignant cells in each section was graded according
Table 2 Features of the primary tumours regarding primary treatment regimen, follow up time and cause of death
(Continued)
54 42 larynx 3 mutation outside L2/
L3/LSH motif
Yes Yes 144 144 No
55 71 larynx 1 wild type p53 Yes Yes 145 145 No
56 59 larynx 4 mutation in L2/L3/LSH
motif
Yes Yes 155 155 Yes
58 74 pharynx 4 mutation outside L2/
L3/LSH motif
No Yes 29 32 Yes
59 56 oral
cavity
3 wild type p53 Yes Yes 163 163 No
60 69 larynx 4 mutation in L2/L3/LSH
motif
Yes Yes 22 22 No
61 63 larynx 3 mutation in L2/L3/LSH
motif
No Yes 15 15 No
62 74 larynx 2 wild type p53 Yes Yes 25 25 No
63 69 larynx 3 mutation in L2/L3/LSH
motif
Yes No 5 7 Yes
64 56 larynx 3 mutation in L2/L3/LSH
motif
Yes Yes 151 151 No
65 75 larynx 3 wild type p53 Yes Yes 20 25 Yes
68 76 pharynx 4 SSCP positivity No only palliative 0 4 Yes
69 65 larynx 2 mutation outside L2/
L3/LSH motif
No Yes 12 43 Yes
70 68 sinonasal 4 wild type p53 Yes Yes 160 160 No
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with a negative reaction, 1% > ≤ 5% as +, >6% ≤10% as
++ >11% ≤40% as +++ and > 40% as ++++.
TP53 mutation analysis strategy
We analyzed TP53 mutations in exons 5-8, where most
of the mutations occur in human tumours (http://www-
p53.iarc.fr/) by using a temperature-controlled non-
radioactive single-strand conformation polymorphism
(SSCP) analysis [22,23]. A sample was judged to be posi-
tive for a TP53 mutation in SSCP only if two indepen-
dent amplified PCR products contained similar shifted
band patterns. Artefacts due to formalin-fixation or the
infidelity of the polymerase-enzyme in PCR were ruled
out by repeating the analysis. Further characterisation of
TP53 mutations was carried out by semi-automatic
sequencing: the PCR amplified samples were sequenced
with an ABI PRISM 3100 sequencer and BigDye Termi-
nator Sequencing Kit (Applied Biosystems, Foster City,
CA).
Amplification of p53 exons by PCR
Exons 5-8 of the TP53 gene were separately amplified by
PCR using two sets of intron primers, the second set
internal to the first, i.e. nested primers [24]. The follow-
ing reagents and concentrations were used in the ampli-
fications: For the primary PCR, formalin-fixed paraffin-
embedded tumour DNA were used as a template in a
total volume of 100 μl with 3.0 U of Dynazyme DNA
polymerase (Finnzymes, Finland), in a buffer containing
10 mM Tris-HCl (pH 8.8), 1.5mM MgCl2, 50mM KCl
and 0.1% Triton X-100, 20-40 pmol of each primer and
300 μl of dNTPs (Pharmacia Biotech, Finland). The
amplification was carried out by 35 cycles including
denaturation at 94°C for 1 min, annealing at 60°C for 1
min and elongation at 78°C for 30 seconds. Secondary
PCR was done in a total volume of 200 μla n d5μlo f
amplified DNA from the primary PCR was used as a
template. To check for possible contamination, the first
and the last reactions in each PCR series were controls
with no template in the reaction. If a band appeared
indicating contamination, the whole series of PCR reac-
tions was disposed of, and the analysis redone. The
amplified products were purified by agarose gel electro-
phoresis, as described earlier [25].
Single-strand conformation polymorphism (SSCP) analysis
and sequencing
A non-radioactive PCR-SSCP method was used as pre-
viously described [19,25] with the Pharmacia PhastSys-
tem
® semi-dry electrophoresis equipment. Two different
temperatures (4°C and 20°C) were used to obtain good
efficiency. Several studies have shown that the optimiza-
tion of SSCP conditions is essential for analytical
sensitivity and efficiency (for review see) [26]. Both
negative and positive controls were included in each run
to ensure the quality of the run. As a negative control,
gel-purified, amplified normal TP53 DNA was used. The
controls were confirmed to be negative by selecting
samples where bands looked the same in SSCP as in for-
mer controls, and by additionally sequencing them to
confirm the wild-type. As a positive control, DNA was
amplified using artificially mutated primers [22]. The
gels were stained with silver staining kit (Pharmacia Bio-
tech, Finland) according to the instructions from the
manufacturer.
Statistical analysis
The correlations of tumour stage, TNM classification,
histological grade, gender, age, and primary anatomical
site were analyzed separately according to the TP53
gene mutations and p53 immunoreactivity. Disease-free
time (DFT), disease-specific survival (DSS) and overall
survival (OS) were analysed for the HNSCC patients
with respect to p53 protein staining and TP53 muta-
tions, using the Kaplan-Meier method and Fisher’s exact
test. Survival was defined as the time from the date of
diagnosis to death due to the cancer or the date of the
last follow-up visit. Disease-free time was defined as the
time from diagnosis of the cancer to recurrence or
death to cancer. Overall survival and disease-specific
survival time was calculated from the date of diagnosis
until death. The patients were censored on the date of
the last follow-up examination or the date of the collec-
tion of clinical data, 24/11/2009. Probability values <
0.05 were considered to be statistically significant. All
statistical analyses were performed using the SPSS soft-
ware system (SPSS for Windows, version 16.0, Chicago,
IL).
Results
General outcome
The mean follow-up of patients was 80 months (range
1-166 mo). At the time of analysis (11/2009), 39% (18 of
46) of the patients had relapsed and died for cancer.
Disease-specific 5-year survival was 60.7% and overall
survival 52.2% for the whole series. Overall 5-year survi-
val was 41.2% in the group of the patients with a T3 or
T4 tumour.
Mutation analysis of TP53 gene
Judging by SSCP the TP53 gene was mutated in a total
of 26 primary tumours (57%) in the 46 HNSCC patients
[19]. Overall, 39 TP53 mutations were identified in
these 26 tumours and sequencing was possible in 23
tumour samples. The features of the TP53 mutations
are summarized in Table 2. When taking into account
the functional and structural domains of p53 as
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www-p53.iarc.fr/) [17]: 22% (8/36) of the mutations
affect the L2 domain (between codons 164 and 194),
which is needed for the correct folding and stabilization
of the central part of the protein, 11% (4/36) affect the
LSH (loop-sheet-helix) motif (codons 119-135 and 272-
287), and 8% (3/36) affect the L3 domain (between
codons 237-250), directly involved in the interaction
between the protein and DNA. Details of the characteri-
zation of the mutations have been published separately
[19].
Comparison of p53 aberrations with clinical
characteristics
The p53 expression levels, as well as the presence of
TP53 mutations were compared with the clinical data.
The p53 aberrations have been published previously and
they do not associate with histological grade, TNM clas-
sification, the stage of the disease or the age of the
patients [19]. Furthermore, even when comparing the
specific TP53 mutations (e.g. TP53 mutations in DNA-
binding domains and TP53 mutations outside those
regions) and stage, TNM-classification or tumour histo-
logical grade, there was no differences between those
two groups.
Disease recurrence and survival of HNSCC patients
related to p53 alterations
The p53 levels as well as the presence of TP53 muta-
tions were compared with the clinical data. There was
no difference in survival or disease recurrence in
patients when all TP53 mutations or different grades of
p53 expression were taken on account. Patients affected
by tumours with TP53 mutations in the DNA-binding
domains L2, L3 or LSH, however, had a shorter survival.
This trend was also seen when disease-specific death
was compared: Patients who had TP53 mutations in L2,
L3 and LSH motifs died of cancer more often (7 out of
9 cases, 77.7%), than patients with a wild-type p53 in
their tumour (8 out of 19, 42.1%) or patients with
tumours presenting a mutation outside L2/L3/LSH
domain (2 out of 8 cases, 25%). We also noticed that
patients with TP53 mutations in L3/LSH motif had
more node metastases (83%) compared to patients with
a wild-type tumour (50%). However, this difference was
not statistically significant (p = 0.2). An interesting find-
ing was that the patients with TP53 mutations in DNA
binding surface region had a higher number of late
residives than the patients with a wild-type p53 or
patients with TP53 mutations outside the functional
domains of p53. The patients with TP53 mutations in
motifs L2/L3/LSH relapsed more often (eight relapses of
13 cases vs. two relapses of 10 cases) and their disease
free survival time was shorter than in other cases (5-yrs
rate 20% vs. 61.5%, p < 0.05, Figure 1A).
Interestingly, patients that had mutations outside the
functional domains of TP53 in the primary tumours sur-
vived longer than the patients with a wild-type p53 in
their tumour. The group of 13 patients with TP53 muta-
tions affecting the DNA-binding domain had a statisti-
cally significantly shorter disease-specific survival time
(5-yrs survival 43.5% vs. 77.8%, p < 0.05, Figure 1B) and
a trend for a shorter overall survival time at the time for
analysis 11/2009, p = 0.06 (5-yrs rate 30.8% vs. 70.0%, p
< 0.05, Figure 1C) than patients with mutations outside
the DNA-binding region. Strong p53 staining was asso-
ciated with a better disease free time, but no correlation
was found between the overall survival and p53 staining.
TP53 mutations and cancer treatment
The patients with TP53 mutations in L3/LSH motif had
significantly poorer response to radiation than patients
with a wild type p53 or TP53 mutations outside the
DNA-binding regions (11.4% vs. 48.6% vs.40% p < 0.05,
Pearson Chi-Square Test). Moreover, patients with TP53
mutations in important DNA-binding motifs L2, L3, or
LSH received less combined treatment (surgery and
radiotherapy), compared to patients with a TP53 muta-
tion outside the L2/L3/LSH motif or a wild-type p53
(14% vs. 60.5%, p = 0.009). On the other hand, patients
treated with combined treatment had a longer disease-
free-time (5-years in 71.2% vs. 37.9%, p < 0.05, Figure
2A), cancer-specific-survival (5-yrs survival 71.6% vs.
34.2%, p = 0.01, Figure 2B), and overall survival (5-yrs
57.6% vs. 30.8%, p < 0.05, Figure 2C). There was no dif-
ference in the treatment modalities between the differ-
ent age-groups or basic diseases. In groups with
different treatment modalities the patient outcome var-
ied: The 5-year disease-specific survival was 75.2% in
the group treated with the preoperative radiotherapy,
69.9% with postoperative radiotherapy and only 40% in
the group with surgery alone. This difference between
the treatment groups almost reached statistical signifi-
cance (p = 0.05).
Discussion
In the present study, we have evaluated the prognostic
value of TP53 gene aberrations in a series of 46
patients with primary head and neck squamous cell
carcinoma. Analysis of TP53 mutations is being stu-
died as a clinical marker [27]. When correlating results
from mutation analysis to the outcome in HNSCC, so
far restricted to exons 5-8 or 5-9, contradicting results
have been published (for reviews see [28,29]). We
found that tumours containing TP53 mutations in
DNA-binding surface regions (L2, L3 + LSH) are more
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those regions. Interestingly, patients affected by
tumours with TP53 mutations in L3 and LSH have
poorer survival, and in case of tumours with TP53
mutations in domains L2, L3 + LSH there were more
relapses and shorter disease free time than with other
tumours implicating a more aggressive phenotype.
Similar findings have already been reported in gastric
cancer [30], and colorectal carcinoma [31]. Bazan and
co-workers (2005) reported that in sporadic colorectal
carcinoma tumours with TP53 mutations in L3 domain
are associated with a worse prognosis (as judged by
disease free time only) than other tumours [31].
Furthermore, several studies have revealed a strong
association between the mutations in the L2/L3 loop
and a shorter survival or poorer response to treatment
in breast cancer [32,33] and in oesophageal cancer
[34]. Oral squamous cell cancers with TP53 mutations
in DNA-binding surface regions (L2, L3 and the LSH
motif) and conserved regions (II-IV) were also
associated with a significantly poorer prognosis than
tumours with mutations outside of those regions [35].
In a large multi-centre study of squamous cell head
and neck cancer, Poeta and co-workers (2007) found
that mutations affecting the protein structure and
DNA-binding capacity of TP53 were associated with
shortened disease-specific and overall survival [36]. In
our study, most (78%) patients that had TP53 muta-
tions in L2, L3 and LSH motifs died of cancer. Only
42% of those patients with a wild type TP53 or 12.5%
in those with TP53 mutations outside the L2/L3/LSH
domain died of cancer. Interestingly, the patients with
mutations outside the DNA-binding domains of p53
had a better survival than the patients with a wild-type
p53. The association between TP53 mutation types and
outcome presented here is also in agreement with the
largest study on the TP53 mutation types and associa-
tion with clinical phenotypes carried out in 630
patients screened for mutations in breast cancer and
published by Alsner and co-workers (2008) [37].
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Figure 1 TP53 mutation status and survival in patients with TP53 mutations in DNA-binding domains and in patients with mutations
outside the DNA-binding domains. A. Disease-free time. B. Disease-specific survival. C. Overall survival.
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specific or overall survival in HNSCC patients with and
without TP53 mutations, no difference was seen
between the two groups. Similarly, some researchers
have failed to find such a correlation [38,39]. On the
other hand, positive association between the TP53
mutations and poor prognosis have been published
[36,40,41]. Patients with TP53 mutations have been
s h o w nt oh a v eas i g n i f i c a n t l ys h o r t e rs u r v i v a lt i m et h a n
those without any TP53 mutations [42]. Also the loco-
regional control rate and disease-free survival rate have
been shown to be inferior in the patient group with a
TP53 mutation when compared to the patients with a
wild-type TP53 [43]. We show here that TP53 mutations
in exons 6 and 8 correlate with poorer overall survival.
Russo and co-workers (2006) have noticed that TP53
mutations within exons 5 and 8 are strong prognostic
indicators of both disease recurrence and survival in
patients with locally advanced laryngeal squamous cell
carcinoma [41]. Similarly, Huang and co-workers (1998)
have studied 204 cases of non-small cell lung carcinoma,
and patients with mutations in exons 7 and 8 have a sig-
nificantly shorter survival compared with patients with
other mutations or no mutation [44]. Our findings
together with the published data suggest that the nature
and location of the mutation are connected to tumour
aggressiveness and prognosis and it is not enough to
analyze merely the presence or absence of the TP53
mutations. Thus, the usefulness of TP53 mutations in
human tumours for clinical purposes requires a much
more detailed analysis.
We found here that patients with TP53 mutations in
L2, L3 or LSH motif received significantly less often
combined treatment (curative intent) and had signifi-
cantly lower disease-free time and cancer specific-survi-
val. Therefore, specific TP53 mutations present in L2,
L3 and LSH motifs could lead to inherently more
aggressive tumours than mutations outside of these
regions. The age of the patients or other diseases did
not affect the treatment modalities. Mechanism of



Disease-Free Time (months) Disease Specific Survival (months)
Overall Survival (months)
P < 0.05 P = 0.01
P < 0.05
Survival Functions Survival Functions
Survival Functions       
Figure 2 Cancer treatment and prognosis. Patients treated with combined treatment had a better disease-free time (A), disease-specific-
survival (B), as well as overall survival (C).
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Many studies have shown that although mutant p53
proteins often lose the ability to activate the expression
of genes that are responsive to wild-type p53, they may
not be inert when it comes to the regulation of tran-
scription [16]. Indeed, a mutant p53 can acquire the
ability to both positively and negatively regulate gene
expression, which clearly contributes to some of the
pro-tumorigenic functions of a mutant p53, such as
enhanced survival and resistance to cancer therapy
[16,47].
There have been a limited number of inconclusive stu-
dies on TP53 mutations in patients treated with primary
radiotherapy (for a review, see [48]). We evaluated the
relationship between TP53 mutations and radiosensitiv-
ity in 36 patients with HNSCC who underwent primary
radiotherapy. Tumours containing TP53 mutations in
DNA-binding surface region had significantly poorer
responses to radiation than other tumours. Eriksen and
co-workers (2005) have investigated the importance of
TP53 mutations for the overall treatment time of radio-
therapy in HNSCC patients [39]. They noticed that
patients with carcinomas containing a wild-type p53 did
not benefit as much as the patients with a mutated
TP53 from an increase in the number of weekly frac-
tions (i.e. a reduction in the overall treatment time), as
judged by local control at T-site, disease-specific or
crude survival [39]. This may be due to the decreased
ability of some mutant p53 proteins to initiate apoptosis
[49]. Consequently, there may be less delay in G1 result-
ing in increased progress through the cell cycle and
increased uncontrolled proliferation [39]. Moreover, Als-
ner and co-workers (2001b) noticed that majority of
head and neck of tumours with a mutated TP53 had a
tumour potential doubling time below that in wild type-
tumours [50]. Carcinomas with a mutated TP53 had
higher cell proliferation potential compared to wild
type-tumours. TP53 mutation status may thus identify
patients where the dominating factor associated with
outcome is an increased intrinsic radioresistance.
Conclusions
In conclusion, this study demonstrates that the clinical
outcome for head and neck cancer patients is associated
w i t ht h et y p eo fTP53 mutations. Mutations present in
DNA-binding regions were associated with poorer prog-
nosis and clinical response to radiotherapy. Especially,
TP53 mutations in L2 and L3 + LSH motif may be usable
as a marker for selecting the treatment option and predict-
ing prognosis among HNSCC. Predictive factors become
increasingly important, in particular because new treat-
ment modalities e.g. radiotherapy combined with EGFR
generally yield more treatment-related toxicity. However,
due to the small number of patients in this study further
confirmation is required before reliable clinical application
is possible. Studies are needed to evaluate whether specific
TP53 mutations influence prognosis in patients treated
with conventional chemoradiotherapy or radiotherapy
combined with anti-EGFR treatment.
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